Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

HomeStyles-Adults of Chinese Heritage

NCT06136793
View directory record Official record
Conditions
Healthy Lifestyle, Home Environment Related Disease, Cardiometabolic Disease, Systemic Inflammatory Response, Health Behavior, Dietary Habits, Physical Inactivity, Self Efficacy, Gut Microbiota, Diabetes Mellitus
Interventions
HomeStyles-China
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

NCT01280695
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
14
States / cities
Goodyear, Arizona • Chula Vista, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 25, 2026, 4:27 PM EDT
Recruiting Not applicable Interventional

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma

NCT07541404
View directory record Official record
Conditions
Subdural Hematoma
Interventions
NeoCast Embolic System, Onyx LES, an FDA-Approved Commercial Liquid Embolic
Device
Lead sponsor
Arsenal Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Results available

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

NCT01933672
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT02769481
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 25, 2026, 4:27 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

NCT02687451
View directory record Official record
Conditions
Post-Operative Pain, Acute Pain
Interventions
Oxymorphone HCl, Placebo
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
0 Years to 2 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 25, 2026, 4:27 PM EDT
Suspended Phase 1 Interventional

Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT04643769
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ORIN1001, Placebo
Drug
Lead sponsor
Orinove, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Clearwater, Florida • Jacksonville, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

NCT02568319
View directory record Official record
Conditions
Central Abdominal Bulging
Interventions
LIPO-202, Placebo
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
6
States / cities
Encinitas, California • Manhattan Beach, California • Aventura, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin in Respiratory Failure in Patients With COVID-19

NCT04350593
View directory record Official record
Conditions
COVID-19
Interventions
Dapagliflozin 10 milligram (mg), Placebo
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Fairhope, Alabama • Miami, Florida • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 25, 2026, 4:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Stanford Center for Back Pain

NCT02503475
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Real-Time fMRI, CBT or MBSR, Acupuncture
Other · Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

NCT06737042
View directory record Official record
Conditions
Obesity and Overweight
Interventions
GZR18, Tirzepatide
Drug
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Bessemer, Alabama • Centreville, Alabama • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 4:27 PM EDT
Recruiting Not applicable Interventional

Satavari and Ashoka for Menopause (SAM) Study

NCT07861295
View directory record Official record
Conditions
Menopause
Interventions
Ashoka Bark and Shatavari, Placebo
Dietary Supplement · Other
Lead sponsor
Vidya USA Corporation
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant

NCT01928199
View directory record Official record
Conditions
Posttransplant Diabetes Mellitus
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

NCT05176093
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Engensis, Placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 25, 2026, 4:27 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577
View directory record Official record
Conditions
Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
34
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

NCT00698230
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB013739, Placebo comparator matching INCB013739, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Artesia, California • Calabasas, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 25, 2026, 4:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients

NCT02315144
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
TV48108, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Medford, Oregon • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Not applicable Interventional

Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle

NCT01289444
View directory record Official record
Conditions
HIV
Interventions
FAmily CEntered (FACE) ACP, Healthy Living Control
Behavioral
Lead sponsor
Maureen Lyon
Other
Eligibility
14 Years to 21 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Fort Lauderdale, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort

NCT01294540
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Drug: E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Not applicable Interventional

taVNS to Reduce PTSD Symptoms in WTC Responders

NCT05212714
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
taVNS
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 25, 2026, 4:27 PM EDT
Not listed Not applicable Interventional

Effects of a Multispecies Probiotic on Migraine

NCT04696458
View directory record Official record
Conditions
Migraine, Irritable Bowel Syndrome, Headache, Migraine
Interventions
Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483), Placebo Comparator: Placebo
Dietary Supplement · Other
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 25, 2026, 4:27 PM EDT
Recruiting Not applicable Interventional

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

NCT06880835
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control IQ + sleep or exercise activity with TI
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder

NCT03835117
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Wide-spectrum nutritional supplement, Placebo
Drug · Other
Lead sponsor
Rossignol Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 25, 2026, 4:27 PM EDT